Standard Molecular Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $1.44M

  • Investors
  • 1

Standard Molecular General Information

Description

Developer of a purpose-engineered genomic testing system designed to access discrete genomic data. The company's system offers personalized medicine, genetic testing, and cancer genomics and presents distinctive opportunities to clinicians, enabling clinicians in diagnostic and therapeutic innovation to optimize workflow and integrate data with existing information systems in the laboratory and across the health system.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Healthcare Technology Systems
Other Industries
Biotechnology
Corporate Office
  • One Broadway
  • 14th Floor
  • Cambridge, MA 02142
  • United States
+1 (617) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Standard Molecular Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 09-Apr-2018 $1.44M 00.000 00.000 Completed Generating Revenue
1. Early Stage VC 08-Apr-2016 00000 00000 00.00 Completed Generating Revenue
To view Standard Molecular’s complete valuation and funding history, request access »

Standard Molecular Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Seed 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
To view Standard Molecular’s complete cap table history, request access »

Standard Molecular Patents

Standard Molecular Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220044810-A1 Integrated diagnostic test requisition and clinical decision support Active 05-Aug-2020 000000000 0
US-11798687-B2 Integrated diagnostic test requisition and clinical decision support Active 05-Aug-2020 000000000 00
US-20240013922-A1 Integrated diagnostic test requisition and clinical decision support Pending 05-Aug-2020 G16H50/20

Standard Molecular Executive Team (5)

Name Title Board Seat Contact Info
Jim D'Augustine Vice President of Product Development
You’re viewing 1 of 5 executive team members. Get the full list »

Standard Molecular Board Members (4)

Name Representing Role Since
Adam Lessler MD Evidity Health Capital Board Member 000 0000
Andrew Smith Self Board Member 000 0000
Paul Enever Ph.D Evidity Health Capital Chairman 000 0000
You’re viewing 3 of 4 board members. Get the full list »

Standard Molecular Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Standard Molecular Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Evidity Health Capital Growth/Expansion Minority 000 0000 000000 0
To view Standard Molecular’s complete investors history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »